Cellyan Biotechnology Co., Ltd Class A Ordinary Shares (HKPD) is a publicly traded Industrials sector company. As of September 24, 2026, HKPD trades at $0.12 with a market cap of $6.02M and a P/E ratio of 0.00. HKPD moved +0.67% today. Year to date, HKPD is -85.23%; over the trailing twelve months it is -91.78%. Its 52-week range spans $0.10 to $2.76. Rallies surfaces HKPD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cellyan Biotechnology appoints Letao Zhao as independent director and compensation committee chair: Letao Zhao joined Cellyan Biotechnology’s board as an independent director and became compensation committee chair, effective Sept. 18, 2026, replacing Mike Yao Zhou, who resigned from the board and stepped down from four committees.
| Metric | Value |
|---|---|
| Price | $0.12 |
| Market Cap | $6.02M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.76 |
| 52-Week Low | $0.10 |
| Volume | 56.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
HKPD analyst coverage data. Average price target: $0.00.